

We Claim:

1. A crystal of a 30S subunit bound to an antibiotic Z, (wherein Z is defined below), having a tetragonal space group $P4_12_12$ with unit cell dimensions, for each of the antibiotics Z, of:

5

Z	a(Angstroms)	b(Angstroms)	c(Angstroms)
Paromomycin	401.375	401.375	175.887
Paromomycin	401.2	401.2	176.4
Streptomycin	401.375	401.375	175.887
Spectinomycin	401.375	401.375	175.887
Tetracycline	401.158	401.158	176.944
Pactamycin	401.719	401.719	177.002
Hygromycin B	402.063	402.063	175.263

2. A crystal of a 30S subunit bound to the antibiotic paromomycin having a tetragonal space group $P4_12_12$ with unit cell dimensions of $a = 401.4 \text{ \AA}$, $b = 401.4 \text{ \AA}$, $c = 175.9 \text{ \AA}$.

3. A crystal of a 30S subunit bound to the antibiotic paromomycin having a tetragonal space group $P4_12_12$ with unit cell dimensions of $a = 402.0 \text{ \AA}$, $b = 402.0 \text{ \AA}$, $c = 176.5 \text{ \AA}$.

4. A crystal of a 30S subunit bound to the antibiotic paromomycin having a tetragonal space group $P4_12_12$ with unit cell dimensions of $a = 401.2 \text{ \AA}$, $b = 401.2 \text{ \AA}$, $c = 176.4 \text{ \AA}$.

5. A crystal of a 30S subunit bound to the antibiotic Streptomycin having a tetragonal space group $P4_12_12$ with unit cell dimensions of $a = 401.4 \text{ \AA}$, $b = 401.4 \text{ \AA}$, $c = 175.9 \text{ \AA}$.

6. A crystal of a 30S subunit bound to the antibiotic Streptomycin having a tetragonal space group $P4_12_12$ with unit cell dimensions of $a = 402.0 \text{ \AA}$, $b = 402.0 \text{ \AA}$, $c = 176.5 \text{ \AA}$.

7. A crystal of a 30S subunit bound to the antibiotic Spectinomycin having a tetragonal space group $P4_12_12$ with unit cell dimensions of $a = 401.4 \text{ \AA}$, $b = 401.4 \text{ \AA}$, $c = 175.9 \text{ \AA}$.

8. A crystal of a 30S subunit bound to the antibiotic Spectinomycin having a tetragonal space group $P4_12_12$ with unit cell dimensions of $a = 402.0 \text{ \AA}$, $b = 402.0 \text{ \AA}$, $c = 176.5 \text{ \AA}$.

9. A crystal of a 30S subunit bound to the antibiotic Tetracycline having a tetragonal space group $P4_12_12$ with unit cell dimensions of $a = 401.2 \text{ \AA}$, $b = 401.2 \text{ \AA}$, $c = 176.9 \text{ \AA}$.

10. A crystal of a 30S subunit bound to the antibiotic Pactamycin having a tetragonal space group $P4_12_12$ with unit cell dimensions of $a = 401.7 \text{ \AA}$, $b = 401.7 \text{ \AA}$, $c = 177.0 \text{ \AA}$.

11. A crystal of a 30S subunit bound to the antibiotic Hygromycin B having a tetragonal space group $P4_12_12$ with unit cell dimensions of $a = 402.1 \text{ \AA}$, $b = 402.1 \text{ \AA}$, $c = 175.3 \text{ \AA}$.

12. A crystal of a 30S ribosomal subunit bound to an antibiotic selected from the group paromomycin, streptomycin, spectinomycin, tetracycline, pactamycin and hygromycin B, having a resolution better (numerically less) than about 3 \AA .

13. A crystal of a 30S ribosomal subunit bound to an antibiotic having the structure defined by the co-ordinates of a table selected from the group of tables 1 to 4.

14. A computer-based method of rational drug design which comprises:
providing the structure of a 30S ribosomal subunit as defined by the coordinates of a table selected from the group of tables 1 to 4;
providing the structure of a candidate modulator molecule; and
fitting the structure of candidate to the structure of the 30S of said table.

15. A computer-based method for identifying a potential inhibitor of the 30S ribosome comprising the steps of:

a. employing a three-dimensional structure of 30S, or at least one sub-domain thereof, to characterise at least one active site, the three-dimensional structure being defined by atomic coordinate data according to a table selected from the group of tables 1 to 4; and

b. identifying the potential inhibitor by designing or selecting a compound for interaction with the active site.

16. The method of claim 15 which further comprises:

c. obtaining or synthesizing the potential inhibitor;
d. contacting the potential inhibitor with 30S to determine the ability of said inhibitor to interact with the 30S.

17. The method of claim 15 which further comprises:

c. obtaining or synthesising said potential ligand;
d. forming a complex of 30S and said potential ligand; and
e. analysing said complex by X-ray crystallography to determine the ability of said potential ligand to interact with 30S.

18. A computer-based method of rational drug design which comprises:

providing the coordinates of at least one atom of a table selected from the group of tables 1 to 4 of the 30S ribosome;

providing the structure of a candidate inhibitor molecule;

fitting the structure of candidate to the coordinates of the 30S ribosome provided to obtain a result; and

comparing said result with a structure comprising the coordinates of the 30S ribosome provided and at least one atom from one antibiotic structure of said table.

19. The method of claim 18 wherein the coordinates comprise a subdomain of the 30S ribosome.

20. The method of claim 18 wherein the coordinates are selected from at least one member of any one of the following groups of residues:

Group I: G1405, A1408, C1490, G1491, A1493, G1494 and U1495;

Group II: G1064, C1066, G1068 and C1192;

Group III: U14, C526, G527, A913, A914, C1490, G1941 and S12Lys45;

Group IV: A965, G966, G1053, C1054, C1195, U1196, G1197 and G1198;

Group V: U244, A892 and C893;

Group VI: G693, A694, C788, C795, C796, S7Gly81, and optionally U1540; and

Group VII: C1403, G1405, G1494, U1495, C1496 and U1498.

- 5 21. A computer system, intended to generate structures and/or perform rational drug design for the 30S ribosome or complexes of the 30S ribosome with a potential modulator, the system containing either (a) atomic coordinate data according to a table selected from the group of tables 1 to 4, said data defining the three-dimensional structure of 30S or at least one sub-domain thereof, or (b) structure factor data for 30S, said structure factor data being derivable from the atomic coordinate data of a table selected from the group of tables 1 to 4.
- 10

22. A computer readable media with either (a) atomic coordinate data according to a table selected from the group of tables 1 to 4 recorded thereon, said data defining the three-dimensional structure of the 30S ribosome, at least one atom or at least one sub-domain thereof, or (b) structure factor data for the 30S ribosome recorded thereon, the structure factor data being derivable from the atomic coordinate data of a table selected from the group of tables 1 to 4.